Evaluating the Role of Hepatobiliary Phase of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Predicting Treatment Impact of Lenvatinib and Atezolizumab plus Bevacizumab on Unresectable Hepatocellular Carcinoma.

atezolizumab bevacizumab biomarkers catenins hepatocellular carcinoma lenvatinib

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
06 Feb 2022
Historique:
received: 16 01 2022
revised: 02 02 2022
accepted: 04 02 2022
entrez: 15 2 2022
pubmed: 16 2 2022
medline: 16 2 2022
Statut: epublish

Résumé

Atezolizumab plus bevacizumab therapy has high response rates in patients with unresectable hepatocellular carcinoma (HCC). The hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging (EOB-MRI) has been reported to be useful as an imaging biomarker for detecting β-catenin mutations. We evaluated whether the pretreatment of the hepatobiliary phase of EOB-MRI could predict the therapeutic effect of lenvatinib and atezolizumab plus bevacizumab. This study included 68 patients (lenvatinib group ( The hyperintensity type (RER ≥ 0.9) was 18.2% in the lenvatinib group and 20.0% in the atezolizumab plus bevacizumab group. In the lenvatinib group, progression-free survival (PFS) was not different between the heterogeneous and homogenous types ( The hepatobiliary phase of EOB-MRI was useful for predicting the therapeutic effect of atezolizumab plus bevacizumab therapy on unresectable HCC.

Sections du résumé

BACKGROUND BACKGROUND
Atezolizumab plus bevacizumab therapy has high response rates in patients with unresectable hepatocellular carcinoma (HCC). The hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging (EOB-MRI) has been reported to be useful as an imaging biomarker for detecting β-catenin mutations. We evaluated whether the pretreatment of the hepatobiliary phase of EOB-MRI could predict the therapeutic effect of lenvatinib and atezolizumab plus bevacizumab.
METHODS METHODS
This study included 68 patients (lenvatinib group (
RESULTS RESULTS
The hyperintensity type (RER ≥ 0.9) was 18.2% in the lenvatinib group and 20.0% in the atezolizumab plus bevacizumab group. In the lenvatinib group, progression-free survival (PFS) was not different between the heterogeneous and homogenous types (
CONCLUSIONS CONCLUSIONS
The hepatobiliary phase of EOB-MRI was useful for predicting the therapeutic effect of atezolizumab plus bevacizumab therapy on unresectable HCC.

Identifiants

DOI: 10.3390/cancers14030827 PMID: 35159095 PMC: PMC8834002
pubmed: 35159095
pii: cancers14030827
doi: 10.3390/cancers14030827
pmc: PMC8834002
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Nat Rev Clin Oncol. 2018 May;15(5):325-340
pubmed: 29508855
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Hepatology. 2021 Oct;74(4):2264-2276
pubmed: 33811765
Eur Radiol. 2015 Jan;25(1):211-20
pubmed: 25063395
Cancers (Basel). 2021 Oct 30;13(21):
pubmed: 34771637
Liver Cancer. 2020 Jun;9(3):275-292
pubmed: 32647631
Cancer Discov. 2019 Aug;9(8):1003-1005
pubmed: 31371324
Liver Cancer. 2021 Aug 19;10(6):615-628
pubmed: 34950184
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
J Exp Clin Cancer Res. 2021 Jun 26;40(1):215
pubmed: 34174931
Curr Oncol. 2021 Oct 14;28(5):4157-4166
pubmed: 34677270
Semin Cancer Biol. 2018 Oct;52(Pt 2):117-124
pubmed: 29229461
Cancers (Basel). 2021 Jun 03;13(11):
pubmed: 34205099
Nature. 2015 Jul 9;523(7559):231-5
pubmed: 25970248
Nat Commun. 2016 Aug 30;7:12624
pubmed: 27571927
J Hepatol. 2014 Nov;61(5):1080-7
pubmed: 24946283
Cancers (Basel). 2021 Jul 20;13(14):
pubmed: 34298844
Clin Cancer Res. 2019 Apr 1;25(7):2116-2126
pubmed: 30373752
Radiology. 2010 Jun;255(3):824-33
pubmed: 20501720
Lancet Oncol. 2020 Jun;21(6):808-820
pubmed: 32502443
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Ann Oncol. 2021 Jun;32(6):801-805
pubmed: 33716105
Liver Cancer. 2021 Jul;10(4):380-393
pubmed: 34414125
Clin Transl Gastroenterol. 2020 May;11(5):e00179
pubmed: 32677805
Anticancer Res. 2019 Aug;39(8):4219-4225
pubmed: 31366509

Auteurs

Ryu Sasaki (R)

Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City 852-8501, Nagasaki, Japan.
ORCID: 0000-0002-0001-7377

Kazuyoshi Nagata (K)

Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City 852-8501, Nagasaki, Japan.

Masanori Fukushima (M)

Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City 852-8501, Nagasaki, Japan.

Masafumi Haraguchi (M)

Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City 852-8501, Nagasaki, Japan.

Satoshi Miuma (S)

Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City 852-8501, Nagasaki, Japan.

Hisamitsu Miyaaki (H)

Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City 852-8501, Nagasaki, Japan.

Akihiko Soyama (A)

Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City 852-8501, Nagasaki, Japan.

Masaaki Hidaka (M)

Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City 852-8501, Nagasaki, Japan.

Susumu Eguchi (S)

Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City 852-8501, Nagasaki, Japan.

Masaya Shigeno (M)

Department Gastroenterology and Hepatology, Japanese Red Cross, Nagasaki Genbaku Hospital, 3-15 Mori-machi, Nagasaki City 852-8511, Nagasaki, Japan.

Mio Yamashima (M)

Department Gastroenterology and Hepatology, Nagasaki Harbor Medical Center, 6-39 Shinchi-machi, Nagasaki City 850-8798, Nagasaki, Japan.

Shinobu Yamamichi (S)

Department Gastroenterology and Hepatology, Nagasaki Harbor Medical Center, 6-39 Shinchi-machi, Nagasaki City 850-8798, Nagasaki, Japan.

Tatsuki Ichikawa (T)

Department Gastroenterology and Hepatology, Nagasaki Harbor Medical Center, 6-39 Shinchi-machi, Nagasaki City 850-8798, Nagasaki, Japan.

Yuki Kugiyama (Y)

Clinical Research Center, National Hospital Organization Nagasaki Medical Center, Department of Hepatology, 2-1001-1 Kubara, Omura City 856-8562, Nagasaki, Japan.

Hiroshi Yatsuhashi (H)

Clinical Research Center, National Hospital Organization Nagasaki Medical Center, Department of Hepatology, 2-1001-1 Kubara, Omura City 856-8562, Nagasaki, Japan.

Kazuhiko Nakao (K)

Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City 852-8501, Nagasaki, Japan.

Classifications MeSH